GHRL and neoplasm: Our data are in agreement with previous reports showing that ghrelin administration prevented tumor and cisplatin-induced muscle wasting, through the down-regulation of inflammation of the p38/c/EBP-beta/myostatin axis and the activation of Akt, myogenin and myoD3.